$ cat ./records/funds-mrna-vaccine-manufacturing-hub-in-africa-to-reduce-continen-2022.txt
Funds mRNA vaccine manufacturing hub in Africa to reduce continent's dependence on imports
[RECORD.TXT] · cat --full
The Gates Foundation contributed to the WHO's Technology Transfer Programme establishing an mRNA vaccine manufacturing hub at Afrigen Biologics in Cape Town, South Africa. The initiative equips African manufacturers to produce mRNA vaccines locally — ending reliance on imported doses that left Africa with the lowest COVID-19 vaccination rates in the world. The hub is designed to be ready for the next pandemic.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Receives the Lasker-Bloomberg Public Service Award for contributions to global health
Next →
Closes Breakthrough Energy Ventures Fund II at $2 billion — largest climate tech VC fund in history
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.